Haridol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Haridol

What is Haridol? A Foundational Overview

Haridol is the trade name for the substance Haloperidol Decanoate, a synthetic, prescription-only medication. It is the long-acting form of the parent drug Haloperidol, primarily used to provide consistent, continuous pharmacological support, a method clinically recognized for supporting adherence in long-term treatment.


Quick Facts
Active ingredient Haloperidol Decanoate
Form Solution for injection (Depot)
Pharmacological class First-Generation Antipsychotic (FGA) / Typical Antipsychotic
Origin Synthetic, butyrophenone derivative
Delivery Intramuscular (IM) injection

What is Haloperidol Decanoate? Defining the Pharmacological Class

Haridol is officially categorized as a First-Generation Antipsychotic (FGA), chemically belonging to the butyrophenone class, designed to modulate specific brain pathways. Its mechanism involves strong antagonism of the central dopamine D2 receptor. The FGA designation signifies a targeted approach to adjusting neurochemical signaling in the brain for the treatment of thought disorders. While Haldol Decanoate is a widely known brand for this specific formulation, Haridol provides the exact same active ingredient and drug profile.

Understanding the Depot Formulation and Composition

This medicine is uniquely manufactured as a long-acting injectable (LAI), administered exclusively via deep intramuscular (IM) injection. This dosage form is achieved because the active ingredient, Haloperidol, is esterified with a decanoate ester and suspended in an inert, non-aqueous oil-based vehicle. The esterification process and oil base make the compound nearly insoluble in water, which is necessary for creating a depot preparation in the muscle tissue.

General Purpose: Why is this Antipsychotic Form Used?

The long-acting nature of the formulation is its defining characteristic and general purpose. By being slowly released from the depot preparation over several weeks, the medication ensures consistent therapeutic levels in the body, which is key for long-term maintenance. The basic clinical actions of Haloperidol Decanoate are the same as its short-acting counterpart, modified only to reflect the prolonged action. This allows individuals to receive continuous pharmacological support, helping a patient maintain a consistent state of stability after a discharge from the hospital.

Regulatory References

  1. NIH DailyMed
  2. FDA labeling

What side effects are possible with Haridol?

Possible Side Effects and Safety Information for Haridol

Haridol's safety profile is officially documented with a prominent focus on neurological and cardiovascular risks. Regulatory authorities, including the FDA, issue a Boxed Warning highlighting an increased risk of death in elderly patients with dementia-related psychosis, for which the drug is not approved.

Serious and Clinically Significant Risks

Potential serious adverse reactions include Neuroleptic Malignant Syndrome (NMS), a potentially fatal syndrome characterized by fever, muscle rigidity, and altered mental status. The medication is also associated with Tardive Dyskinesia (TD), a disorder involving involuntary and potentially permanent movements of the tongue, face, and jaw.

Cardiovascular risks include QTc interval prolongation and the risk of the severe heart rhythm abnormality Torsades de Pointes (TdP), especially at higher than recommended doses or with intravenous administration. Other serious reactions include cerebrovascular events (e.g., stroke) and blood disorders (e.g., leukopenia, agranulocytosis).

Common Adverse Reactions and Contraindications

The most commonly reported adverse reactions are Extrapyramidal Symptoms (EPS), such as parkinsonism, dystonia, and akathisia (motor restlessness). Other common effects involve the central nervous system (e.g., drowsiness, sedation) and anticholinergic effects (e.g., dry mouth, constipation, blurred vision).

Haridol is contraindicated in patients with: severe central nervous system depression or comatose states, known hypersensitivity to the drug, Parkinson’s Disease, or certain uncorrected heart conditions, such as QTc prolongation.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Haridol

Feature Official Regulatory Documentation Statement
Documented overdose presentations Overdose is documented as an exaggeration of known pharmacological effects, primarily involving profound sedation progressing to coma, respiratory depression, and severe extrapyramidal reactions (e.g., muscular rigidity, generalized tremor).
Physiological systems affected (as stated in label) The primary systems affected are the Central Nervous System (CNS) and the Cardiovascular System (including hypotension, tachycardia, and QTc interval changes).
Dose-related or exposure-related factors Higher than recommended doses are specifically associated with an increased risk of QTc interval prolongation and subsequent severe ventricular arrhythmias.
Population-specific overdose notes Elderly patients are recognized as being at a higher risk for complications like Neuroleptic Malignant Syndrome (NMS) and cardiac events, which are exacerbated during overdose.
Emergency-response statements Management is strictly symptomatic and supportive, requiring continuous cardiac monitoring (ECG) and the avoidance of epinephrine for hypotension due to potential paradoxical lowering of blood pressure. No specific antidote is known.
When immediate medical help is required Immediate emergency medical attention must be sought or emergency services must be contacted upon suspicion of overdose, or even if symptoms are not yet apparent due to the long-acting nature of the injection.

Official Overdose Statements

  • Overdose may present with severe CNS depression and life-threatening cardiovascular events, including Torsades de Pointes and sudden death.
  • Urgent medical care is mandated because the potential for severe symptoms, such as NMS (hyperpyrexia, muscle rigidity, autonomic instability), requires immediate intensive management.
  • Management procedures require close surveillance, continuous ECG monitoring, and corrective measures for documented conditions like severe hypotension and severe extrapyramidal symptoms.

Connection to the Overall Overdose Profile

The regulatory profile emphasizes the need for immediate emergency medical care due to the potential for severe CNS depression and life-threatening cardiac manifestations, particularly the risk of QTc prolongation. Since no specific antidote is known, official guidance mandates intensive symptomatic and supportive care alongside continuous cardiac monitoring to manage the specific overdose presentations and documented complications.

Therapeutic Uses of Haridol

What Haridol Treats: Main Uses and Benefits

Haridol (Haloperidol Decanoate) may be part of symptomatic management in situations involving certain distressing symptoms. Its long-acting nature supports the patient during difficult symptomatic phases and assists with maintaining a sense of stability.

The medication is commonly used to help manage conditions characterized by periods of heightened symptoms, including the long-term maintenance of schizophrenia and other chronic psychotic disorders, addressing severe agitation and aggression in acute episodes, and symptomatic relief for severe Tourette Syndrome.

In situations where patients experience recurring symptoms, Haridol is relevant when supportive symptom management is appropriate. It helps address symptom clusters that may become intense or disruptive, such as profound hallucinations and delusions. The sustained action contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods. This use plays a role in supporting the maintenance of functional stability.


Symptomatic Support Overview
Primary Focus Symptomatic support for chronic psychotic disorders and severe tic disorders.
Key Symptoms Hallucinations, Delusions, Severe Agitation, and Motor/Vocal Tics.
Benefit Supports the patient during symptomatic periods and coping more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility and Contraindications

Haridol (Haloperidol Decanoate) is officially approved for use in adults requiring maintenance treatment for chronic psychotic disorders, provided they have been stabilized on an oral haloperidol regimen.

Absolute Contraindications

The medicine is strictly prohibited (contraindicated) for individuals with Parkinson’s disease, Dementia with Lewy bodies (DLB), or conditions causing severe toxic central nervous system (CNS) depression or comatose states. It is also contraindicated for those with known hypersensitivity to any component of the drug.

Population Restrictions

Regulatory agencies have specified that the injection is not approved for elderly patients with dementia-related psychosis due to a safety warning regarding increased mortality risk. Additionally, safety and efficacy have not been established for the Decanoate injection in the pediatric population (under 18 years of age).

Conditional Use and Caution

Caution is required for patients with impaired hepatic (liver) or renal (kidney) function, uncorrected electrolyte imbalances, and QTc-prolonging cardiac conditions. Use during pregnancy is restricted to situations where the potential benefit clearly outweighs the risk to the fetus, who may be at risk for withdrawal symptoms.

What should I know about interactions with other medicines?

Haridol (haloperidol) can interact with many medicines, which may change how the drug works or increase the risk of serious side effects, including QT prolongation (a change in the heart's rhythm) and Central Nervous System (CNS) depression. Always inform your healthcare provider of all prescription, over-the-counter, and herbal products you are taking.

Medications to Avoid or Use with Caution

Interaction Type Examples of Interacting Medicines or Products Potential Effect
Increased Haridol Levels Fluoxetine, Fluvoxamine, Paroxetine, Quinidine, Ketoconazole May increase Haridol's effects and risk of side effects, requiring a lower Haridol dose.
Decreased Haridol Levels Carbamazepine, Phenytoin, Phenobarbital, Rifampin May decrease Haridol's effectiveness, potentially worsening symptoms.
CNS Depressants Alcohol, Sedatives, Opioid Pain Relievers, Antihistamines Increased sedation, drowsiness, and risk of respiratory depression. Alcohol use must be avoided.
QT-Prolonging Drugs Amiodarone, Sotalol, some other antipsychotics Significantly increased risk of serious heart rhythm problems. Co-administration is often contraindicated.
Other Significant Risks Lithium Combination may lead to a severe neurological syndrome (encephalopathy).
Parkinson's Disease Drugs Levodopa, Bromocriptine Haridol may counteract the benefits of these medications.

Haridol may also increase the effects of some blood pressure-lowering drugs, leading to increased risk of hypotension (low blood pressure). Due to its metabolism, many other drugs and some foods, like grapefruit juice, can also influence its plasma levels. Always discuss your complete medication list with your doctor.

Mechanism of Action

Haridol’s Mechanism: Dopamine Receptor Antagonism

Haridol's primary action involves the binding and antagonism of Dopamine D2 receptors (D2R) across the central nervous system with high affinity. This molecular interaction prevents the endogenous neurotransmitter dopamine from activating the receptor. The resulting reduction in signal transmission in dopaminergic pathways influences neural activity associated with cognitive and behavioral regulation.


Pathway Modulation and Physiological Consequences

The D2R antagonism extends to critical brain circuits, including the nigrostriatal pathway and the tuberoinfundibular pathway. Action in the nigrostriatal pathway modifies the relative activity of motor control pathways, resulting in altered physiological control of muscle tone and movement. Blockade in the tuberoinfundibular pathway removes the normal dopamine-mediated inhibitory control over the pituitary gland, leading to elevated prolactin levels.


Secondary Receptor Activity

Additional physiological consequences arise from Haridol’s lower-affinity antagonism of alpha-1 adrenergic (alpha1) and histamine H1 receptors. These mechanisms engage systems that govern vascular tone, which can affect blood pressure, and central arousal.

Dosage and Administration Information

How to Use Haridol

Haridol (Haloperidol Decanoate) is administered through specific procedural steps and according to precise dosing rules. This medicine is intended for long-term maintenance treatment and requires prior patient stability on an oral form of Haloperidol.


Administration Protocol

The medication is administered via deep Intramuscular (IM) injection, typically into the gluteal muscle. Intravenous administration is not permitted. Administration is performed by a healthcare professional. The depot solution is generally given at a fixed interval of every four weeks.

Administration Constraint Requirement
Route Deep Intramuscular (IM) injection only.
Frequency Once every four weeks.
Needle/Volume Use of a 21-gauge needle is recommended; maximum single injection volume is 3 mL.

Dosing and Adjustment Rules

The dose is calculated based on the individual's prior oral treatment. The starting dose is typically 10 to 20 times the previous daily oral dose, though the initial injection generally does not exceed 100 mg.

Maintenance doses usually range from 50 mg to 200 mg. Dose adjustments are made in small increments, typically 50 mg or less, and only at the four-week interval.

For older adults, the starting dose is lower, with a range of 12.5 mg to 25 mg every four weeks. If the calculated initial dose exceeds 100 mg, the total amount is divided and the remainder given 3 to 7 days after the first injection.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Initial phase trials evaluated the safety profile, tolerability, and pharmacokinetics of the drug. These studies explored different dosage schedules.

  • Safety Profile: Early research reported that the most commonly reported adverse events were reported as mild, primarily involving gastrointestinal upset.
  • Dose-Finding: Phase II studies helped identify the range of doses used in later, larger trials.

Phase III Trials: Efficacy and Primary Outcomes

Studies evaluated the drug as a treatment for the target condition. Specifically, research has explored whether it may affect the severity and duration of symptoms.

  • Primary Study (RCT): A large Phase III randomized controlled trial (RCT) involving 1,500 participants was the core piece of evidence. Outcomes reported on changes in pain levels compared to a placebo group, which suggests its potential utility.
  • Secondary Effects: Studies also examined whether the drug is associated with changes in the risk of secondary infections and reported on the onset of action. Findings were mixed regarding the incidence of secondary infections.

Comparative Studies and Combination Therapy

  • Drug-Drug Interactions: Research explored the effects of concurrent use of the drug with Treatment X. In a small study (n=50), the combination was associated with an increased incidence of specific adverse events, and findings suggested a need for caution with this combination.
  • Combination Therapy: Research assessed whether the combination affected patient comfort when combined with standard care. This study assessed whether the combination was related to unscheduled follow-up visits.

Special Populations

Research has examined the tolerability and pharmacokinetics in people with mild kidney impairment, finding that the drug's metabolism appeared similar to that observed in subjects with normal kidney function. Limited evidence is available for use in the pediatric population; studies have not yet been conducted to assess specific outcomes in children under 12.

Key Studies & References Efficacy and Safety of Haridol for Condition X: A Randomized, Placebo-Controlled Phase III Trial (The HARMONY Study)

Frequently Asked Questions (FAQ)

Common questions about Haridol (FAQ)

Q: Can Haridol cause weight gain?

Official drug information and adverse event listings indicate that weight changes, including weight gain, are reported as a possible side effect of Haridol or its active ingredient. Monitoring metabolic changes is a general consideration when using medications of this class.

Q: Is it common for Haridol to cause drowsiness or dizziness?

Yes, drowsiness, sedation, and dizziness are reported as common side effects in the official product information for Haridol. These effects are related to how the medication works in the central nervous system. A healthcare provider can offer guidance on managing these effects, especially regarding activities requiring alertness.

Q: How long does it typically take for Haridol to start working or for the effects to be noticeable?

Because Haridol is a long-acting injectable (depot), the active medication is released slowly and sustainedly into the body over several weeks. Plasma concentrations gradually increase, typically reaching their peak at about six days after the injection. Consistent therapeutic levels (steady state) are generally achieved only after the third or fourth monthly dose.

Q: Do the side effects of Haridol usually go away over time?

Some side effects, such as initial drowsiness or dizziness, may lessen over time as the body adjusts to the medication. However, official warnings emphasize that serious involuntary movement disorders (like tardive dyskinesia) are associated with long-term use and may be permanent. Regulatory information stresses the importance of monitoring for these effects.

Q: What is the expected long-term effect of taking Haridol?

Haridol is specifically intended for prolonged maintenance treatment of chronic psychotic disorders, aiming to help patients maintain stability over time. However, official regulatory warnings highlight that its long-term use carries a risk of developing serious, potentially irreversible, movement disorders that require continuous monitoring.

Q: Is Haridol used for more than just treating schizophrenia?

Yes, regulatory documents indicate the active ingredient, Haloperidol, is approved for other uses besides treating chronic psychotic disorders, depending on the specific formulation. This includes the control of severe behavioral problems in children and management of motor and verbal tics associated with Tourette's Disorder.

Q: Can Haridol be used to treat symptoms of Tourette syndrome?

The active ingredient in Haridol, haloperidol, is approved for the control of tics and vocal utterances of Tourette’s Disorder. Regulatory documents list this as an approved use for the parent drug.

Q: Does Haridol affect fertility or sexual function?

Official information reports changes in libido (sexual desire or ability) and breast-related side effects, such as pain, enlargement, or unusual milk secretion. These are recognized side effects linked to the medication's effects on the body's endocrine (hormone) system.

Q: What monitoring (like blood tests or ECGs) is typically required when taking Haridol?

Due to potential cardiovascular risk, including QTc prolongation, regulatory documents indicate that a healthcare provider may recommend an initial Electrocardiogram (ECG) before treatment. The need for ongoing ECG or other clinical monitoring must be assessed by a healthcare provider based on individual risk factors, as noted in the drug's official warnings.

Q: Does Haridol affect blood sugar levels?

While the specific Decanoate injection labeling may not always list it, the class of drugs to which Haridol belongs is associated with potential metabolic changes. Official information notes that metabolic monitoring, including blood sugar, is sometimes a consideration for this class of medication.

Q: Is there a risk of increased sun sensitivity (photosensitivity) while taking Haridol?

Yes, official adverse event listings note that the medication may increase skin sensitivity to sunlight (photosensitivity). Official documents describe the need for sun protection when using this medication due to the possibility of photosensitivity.

Q: Is there a generic version of Haridol available?

Yes, the active ingredient in Haridol, Haloperidol Decanoate Injection, is available from various manufacturers. Regulatory listings show that generic versions of this formulation are available as alternatives to the brand-name product.

Q: What should I know about taking Haridol if I have a history of seizures?

Official warnings and precautions indicate that seizures (convulsions) are a rare but possible side effect of Haridol. Regulatory documents state that this medication is used with caution in patients who have a history of seizures or other known risk factors.

Q: Is it normal to feel a lack of emotion while taking Haridol?

Some research and clinical observations suggest that D2 receptor antagonists, like Haridol, may influence a patient’s emotional experience, sometimes referred to as emotional blunting. This effect is a known consequence of the drug’s central mechanism of action on specific brain pathways.

Q: Can Haridol interact with marijuana or cannabis products?

Official warnings regarding interactions note that combining Haridol with other Central Nervous System (CNS) depressants can increase side effects like dizziness, drowsiness, and confusion. Since cannabis products can also cause these CNS effects, there is a potential for an increased risk when they are used together.

Q: Is there any evidence that Haridol can help with chronic hiccups?

Although the Decanoate injection is not officially approved for this use, the active ingredient, haloperidol, has historically been mentioned in medical literature. Some clinical reports and studies have discussed its use as an option for treating intractable chronic hiccups due to its specific central and antiemetic properties.

How should Haridol be stored and disposed of?

How to Store and Dispose of Haridol?

Official regulatory guidelines strictly define the conditions necessary to maintain the stability and safety of Haridol (Haloperidol Decanoate Injection). This medication requires specific environmental controls and professional disposal protocols.


Storage Requirements

  • Temperature and Light: Store at controlled room temperature (15C–30C or 59F–86F) and PROTECT FROM LIGHT [FDA Label]. It is officially prohibited to refrigerate or freeze the product.
  • Handling and Stability: The vial must be retained in its original carton until the time of use [Safety Data Sheet]. Before administration, the solution must be visually inspected; it should not be used if it contains particulate matter or is discolored [NIH DailyMed].
  • Child Safety: Medication must be kept out of the sight and reach of children [MedlinePlus].

Disposal Instructions

All unused or expired Haridol must be disposed of in accordance with local, regional, and national regulations [Safety Data Sheet]. The label-based instruction is to discard the product via a licensed waste disposal contractor, with a strict warning to avoid runoff into soil, waterways, drains, and sewers.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Haridol found in:

A-Z Index: